Option chain shows key data for Cann American's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cann American.

Cann American (OTC:CNNA) Stock, Option Chain

Cann American Corp is engaged in developing assets in legal cannabis and hemp industries. It is focused on consulting, infrastructure developming assets, product marketing and strategic acquisitions within the legal cannabis and hemp industries.

Penny Stocks

Short Ideas

Trading Ideas

CNNA

On Thursday, shares of Cann American Corp (OTC: CNNA) experienced volatile short activity. After the activity, the stock price went up +13.89% to $0.0082.

The overall sentiment for CNNA has been Bullish.

Short Volatility Alert: Cann American Corp

Photo: Courtesy Of Warren Umoh On Unsplash

Cannabis

News

Markets

Cann American Corp. (OTCPK: CNNA), a holding company specializing in the development of alternative therapeutics, recently finalized its acquisition of Liberty Health Plus, marking a significant milestone for the company.

CBD Provider For Dogs, Cats &amp; Horses Cann American Corp. Acquires Prodigy Health Plus

Cann American Corp. (OTCPK:CNNA), has entered into a binding letter of intent.

Under the terms of the agreement Cann American will acquire 80 million common shares of Mark2media Group, constituting 80% majority ownership in Mark2, in exchange of 1.5 million series B preferred shares of Cann American.

CannAmerican Stock Plummets On LOI To Acquire Mark2

CANN AMERICAN CORP by Cann American Corp.

Cann American Corp

Wells Fargo analyst Matthew Akers maintains GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) with a Overweight and raises the price target from $225 to $250.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on GE Aero, Raises Price Target to $250

EVAX

Evaxion Biotech Shares Halted On Circuit Breaker To The Downside, Stock Now Up 79.1%

ALUR

Allurion Technologies Shares Halted On Circuit Breaker To The Upside, Stock Now Up 210%

Wells Fargo analyst Larry Biegelsen maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and raises the price target from $630 to $687.

ISRG

Wells Fargo Maintains Overweight on Intuitive Surgical, Raises Price Target to $687

Cantor Fitzgerald analyst Jonathan Fiore reiterates Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Neutral and maintains $200 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Texas Instruments, Maintains $200 Price Target

RNAZ

TransCode Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 35.6%

On Friday, Buy Now, Pay Later (BNPL) firm Affirm&nbsp;Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) will avail $750 million in funding from Liberty Mutual Investments&nbsp;(LMI) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43187378/liberty-mutual-investments-expands-capital-partnership-with-affirm" rel="noreferrer noopener">through June 2027</a>.&nbsp;LMI expects to invest up to $5 billion in the program.
Affirm and LMI began their long-term capital partnership in 2019, followed by their forward flow loan purchase program in 2023.
Affirm stock gained after the report.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/12/42560428/consumer-finance-watchdog-cracks-down-on-credit-card-sneaky-fees-and-false-promises" rel="noreferrer noopener">Consumer Finance Watchdog Cracks Down on Credit Card Sneaky Fees and False Promises</a>
Affirm needs investors&#8217; money to accomplish its 2025 lending target of plus $34 billion, up by ~25% year-on-year, the Wall Street Journal <a target="_blank" href="https://www.wsj.com/finance/affirm-gets-big-financing-check-from-liberty-mutual-71b08757" rel="noreferrer noopener">reported</a>, citing unnamed sources familiar with the matter. As per the report, the insurer initially agreed to invest $250 million in Affirm loans before expanding its commitment to $500 million.
The deal follows Affirm&#8217;s financing arrangements with&nbsp;Sixth Street Partners, which <a target="_blank" href="https://www.benzinga.com/tech/24/12/42486903/affirm-secures-4-billion-loan-deal-with-sixth-street-to-boost-bnpl-growth" rel="noreferrer noopener">agreed to lend $4 billion</a>, and the investment arm of&nbsp;Prudential Financial, which pledged $500 million.&nbsp;
Blue Owl Capital agreed late last year to invest $2 billion in consumer loans originated by&nbsp;Upstart.
As of September 30, 2024, Affirm&#8217;s total funding capacity was $16.8 billion, growing by over 50% over the last two years. Affirm generated over $28 billion in gross merchandise volume (GMV) for the last twelve months ending September 30, 2024.
LMI invests over $100 billion of assets globally across an integrated platform for Liberty Mutual Group of Insurance Companies.
Affirm Holdings stock surged over 40% in the last 12 months as the artificial intelligence&nbsp;frenzy prompted funding activities without diluting ownership by stock issue, enabling a more flexible payment option for customers.
Last October, Wedbush analyst David J. Chiaverini <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41318842/affirm-set-to-drive-gmv-growth-from-lower-interest-rates-and-apple-pay-partnership-" rel="noreferrer noopener">expressed optimism over</a> Affirm Holdings, citing the lower interest rate environment&#8217;s benefits through reduced funding costs and incremental GMV growth.
<h2 class="wp-block-heading">Affirm Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Affirm Holdings, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Affirm Holdings, the 200-day moving average sits at $41.91, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is below the current price of $57.94. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: AFRM stock is up 2.87% at $58.39 at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/media/25/01/43063274/imax-secures-netflix-deal-for-exclusive-narnia-theatrical-release-stock-jumps" target="_blank" rel="noreferrer noopener">IMAX Secures Netflix Deal for Exclusive &#8216;Narnia&#8217; Theatrical Release, Stock Jumps</a></li>
</ul>
Photo via Affirm

Fintech news covering the emerging Financial Technology services sector

Fintech

Movers

Tech

Media

AFRM

Affirm Surges on $750 Million Liberty Mutual Deal, Eyes $34 Billion Lending Target for 2025

Wells Fargo analyst Michael Kaye maintains SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) with a Overweight and raises the price target from $32 to $33.

Wells Fargo Maintains Overweight on SLM, Raises Price Target to $33

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst Chris LaFemina downgraded the rating for Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) from Buy to Hold and lowered the price target from $48 to $40. Freeport-McMoRan shares closed at $38.50 on Thursday. <a href="https://www.benzinga.com/quote/FCX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jeffrey Zekauskas downgraded CF Industries Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) from Neutral to Underweight and slashed the price target from $82 to $75. CF Industries shares closed at $95.24 on Thursday. <a href="https://www.benzinga.com/quote/CF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Michelle Fang downgraded New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) from Buy to Neutral and lowered the price target from $83 to $50. New Oriental Education shares closed at $46.75 on Thursday. <a href="https://www.benzinga.com/quote/EDU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Matthew Boss downgraded the rating for PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) from Overweight to Neutral and slashed the price target from $149 to $113. PVH shares closed at $96.32 on Thursday. <a href="https://www.benzinga.com/quote/PVH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Ronald Epstein downgraded Textron Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) from Buy to Neutral and lowered the price target from $110 to $85. Textron shares closed at $78.21 on Thursday. <a href="https://www.benzinga.com/quote/CCEC/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PVH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24065451/image-186-1024x575.png" alt="" class="wp-image-748564" style="width:443px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24065451/image-186-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24065451/image-186-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24065451/image-186-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24065451/image-186.png 1141w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>

Downgrades

Pre-Market Outlook

New Oriental Education & Technology Group

This PVH Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

DGNX

Diginex Shares Halted On Circuit Breaker To The Downside, Stock Now Down -35.5%

Allurion Technologies Shares Resume Trade

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/01/23/final-trades-freeport-mcmoran-clearway-energy-and-nasdaq.html">Halftime Report Final Trades</a>,&#8221; Bill Baruch of Blue Line Capital said Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) reported quarterly earnings on Thursday. 
Copper is going higher and Freeport-McMoRan<a href="https://www.benzinga.com/news/earnings/25/01/43167826/freeport-mcmoran-misses-q4-revenue-estimates-shares-slide-as-copper-sales-and-revenue-decline"> will follow, he added.</a>
Phoenix, Arizona-based Freeport-McMoRan reported fourth-quarter revenue of $5.72 billion. It missed the consensus of $5.99 billion. Copper sales totaled 1 billion pounds — slightly above the October 2024 estimate. Copper sales declined year-over-year owing to lower ore grades and the timing of shipments at PT-FI.
In the basic materials sector, Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC picked Clearway Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEN#NYSE">CWEN</a>), which is a renewable power generation company.
On the earnings front, Clearway Energy is scheduled to report fourth quarter 2024 financial results on Monday, Feb. 24.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Rounding out the trades, Joshua Brown of Ritholtz Wealth Management said Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) successfully retested the breakout level and is on the rise once again.
Supporting his view, Oppenheimer analyst Owen Lau, on Jan. 13, maintained Nasdaq with an Outperform and raised the price target from $86 to $89.
Price Action:
<ul>
<li>Freeport-McMoRan shares fell 1.5% to close at $38.50 during Thursday's session.</li>
<li>Clearway Energy shares rose by 2.6% to close at $25.28 during Thursday's session.</li>
<li>Nasdaq shares gained 0.3% to close at $81.03 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>
Image: Shutterstock

CWEN

NDAQ

Freeport-McMoRan, Clearway Energy And A Financial Stock On CNBC's 'Final Trades'

Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) reported better-than-expected financial results for the fourth quarter <a href="https://www.benzinga.com/general/health-care/25/01/43178600/intuitive-surgical-q4-earnings-revenue-beat-eps-beat-da-vinci-procedures-jump-18-and-more">after the market close on Thursday.</a>
Intuitive Surgical reported fourth-quarter revenue of $2.41 billion, beating the consensus estimate of $2.25 billion. The robotic-assisted surgery company reported fourth-quarter adjusted earnings of $2.21 per share, beating analyst estimates of $1.79 per share, according to Benzinga Pro.
Intuitive Surgical expects full-year 2025 worldwide da Vinci procedures to increase approximately 13% to 16%. The company expects gross profit margin to be between 67% and 68% of net revenue in 2025.
"We are pleased with customer adoption of da Vinci 5, Ion, and SP during the quarter and full year. We remain focused on delivering the goals we share with our customers, centered on improving patient outcomes," Intuitive Surgical CEO Gary Guthart said in the preliminary release.
Intuitive Surgical shares fell 0.3% to close at $608.66 on Thursday.
These analysts made changes to their price targets on Intuitive Surgical following earnings announcement.
<ul>
<li>JP Morgan analyst Robbie Marcus maintained Intuitive Surgical with an Overweight rating and raised the price target from $575 to $675.</li>
<li>Citigroup analyst Joanne Wuensch maintained the stock with a Buy rating and boosted the price target from $640 to $711.</li>
</ul>
Considering buying ISRG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24083958/image-190-1024x532.png" alt="" class="wp-image-748721" style="width:576px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24083958/image-190-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24083958/image-190-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24083958/image-190-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24083958/image-190.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>

Earnings

These Analysts Boost Their Forecasts On Intuitive Surgical Following Strong Q4 Results

Macro Economic Events

Macro Notification

Econ #s

Economics

General

S&P Global Services PMI 52.8 Vs 56.4 Est.; 56.8 Prior

S&P Global Manufacturing PMI 50.1 Vs 49.8 Est.; 49.4 Prior

Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) reported mixed fourth-quarter <a href="https://www.benzinga.com/25/01/43162202/union-pacific-posts-mixed-q4-results-with-strong-eps-growth-and-improved-efficiency-metrics">results on Thursday</a>.
Union Pacific reported operating revenue decline of 1% year-over-year to $6.121 billion, missing the consensus of $6.143 billion. Earnings per share were $2.91 (+7% year-over-year), above the consensus of $2.78.
Union Pacific anticipates that volume will be impacted by mixed economic conditions, fluctuating coal demand, and challenging year-over-year comparisons in international intermodal.
Pricing is expected to drive improvements in the operating ratio, with earnings per share growth projected to reach high-single to low-double digits over the next three years.
&#8220;Our strong fourth quarter results represent a great capstone to a very successful year for Union Pacific,&#8221; said Jim Vena, Union Pacific Chief Executive Officer. &#8220;The team has fully embraced our strategy to lead the industry in safety, service, and operational excellence. That commitment has produced industry leading financial results in 2024, punctuated by our strong finish to the year. We will carry this momentum into 2025 as we seek to unlock the full potential of the UP franchise.&#8221;
Union Pacific shares fell 0.3% to close at $608.66 on Thursday.
These analysts made changes to their price targets on Union Pacific following earnings announcement.
<ul>
<li>Baird analyst Benjamin Hartford maintained Union Pacific with an Outperform and raised the price target from $260 to $265.</li>
<li>Citigroup analyst Ariel Rosa maintained Union Pacific with a Neutral and raised the price target from $254 to $260.</li>
</ul>
Considering buying UNP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="598" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24084546/image-191-1024x598.png" alt="" class="wp-image-748738" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24084546/image-191-1024x598.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24084546/image-191-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24084546/image-191-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24084546/image-191.png 1082w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>

Union Pacific Analysts Increase Their Forecasts After Q4 Results

<h3 class="wp-block-heading">This Is A Meme Stock</h3>
On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) is a meme stock.
&#8220;I'm never going to get in the way of a meme stock because you never know <a href="https://www.benzinga.com/25/01/43110841/soundhound-ai-shares-are-on-the-rise-today-whats-going-on">how high they can go,&#8221;</a> he added.
Shares of SoundHound AI rose sharply on Tuesday following the announcement of a collaboration with Rekor Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>). The partnership between SoundHound AI and Rekor Systems will integrate SoundHound's voice AI with Rekor's vehicle recognition software, Rekor Scout, to enhance emergency vehicle technology.
<h3 class="wp-block-heading">Buy This Tech Stock</h3>
Cramer recommended buying Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), noting that the stock is &#8220;so cheap.&#8221;
Supporting his view, Keybanc analyst Steve Barger, on Jan. 17, upgraded Lam Research from Sector Weight to Overweight and maintained the price target of $95.
<h3 class="wp-block-heading">Energy Stocks In Focus</h3>
Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) is his &#8220;absolute favorite&#8221; of the group, Cramer said. &#8220;I think you've just got to just stand there and buy it.&#8221;
Adding support to his choice, Truist Securities analyst Neal Dingmann, on Jan. 3, maintained Enterprise Products Partners with a Buy rating and boosted the price target from $37 to $40.
The &#8220;Mad Money&#8221; host said he is not an oil guy here, when asked about Chord Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>).
Analysts, including, Piper Sandler and Wells Fargo also slashed their price targets for the stock on Jan. 15. Piper Sandler analyst Mark Lear lowered the price target from $194 to $193, while Wells Fargo analyst Hanwen Chang cutthe price target from $176 to $175.
Price Action:
<ul>
<li>SoundHound shares gained 0.1% to settle at $16.40 on Thursday.</li>
<li>Lam Research shares fell 2.4% to close at $81.23 during the session.</li>
<li>Enterprise Products Partners shares fell 0.4% to close at $33.67.</li>
<li>Chord Energy shares slipped 1.1% to settle at $120.74 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>
Image: Shutterstock

Long Ideas

CHRD

LRCX

REKR

SOUN

Jim Cramer Won't 'Get In The Way' Of This Meme Stock, Calls Lam Research 'So Cheap'

Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) reported worse-than-expected first-quarter sales results and issued second-quarter revenue guidance below estimates, after the <a href="https://www.benzinga.com/quote/PLXS/earnings">closing bell on Wednesday.</a>
Plexus reported quarterly earnings of $1.73 per share which beat the analyst consensus estimate of $1.59 per share. The company reported quarterly sales of $976.000 million which missed the analyst consensus estimate of $982.220 million.
Plexus said it sees second-quarter adjusted earnings of $1.46 to $1.61 per share, versus market estimates of $1.59 per share. The company projects revenue of $960 million to $1.00 billion, versus expectations of $1.015 billion.
Todd Kelsey, President and Chief Executive Officer, commented, &#8220;Our team&#8217;s agility and responsiveness enabled strong operating performance in the fiscal first quarter, resulting in robust financial results to begin fiscal 2025. We delivered fiscal first quarter revenue of $976 million, in-line with expectations, and non-GAAP operating margin of 6.0%, near the high end of our guidance and consistent with our long-term goal. This contributed to non-GAAP EPS of $1.73, which exceeded guidance. Furthermore, free cash flow generation surpassed expectations, benefiting from the ongoing efforts of our fiscal 2024 initiatives to drive sustained improvement in working capital efficiency.&#8221;
Plexus shares fell 10.1% to close at $153.30 on Thursday.
These analysts made changes to their price targets on Plexus following earnings announcement.
<ul>
<li>Needham analyst James Ricchiuti maintained Plexus with a Buy and raised the price target from $162 to $172.</li>
<li>Benchmark analyst David Williams maintained the stock with a Buy and lifted the price target from $165 to $170.</li>
</ul>
Considering buying PLXS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="600" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24085320/image-192-1024x600.png" alt="" class="wp-image-748764" style="width:548px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24085320/image-192-1024x600.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24085320/image-192-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24085320/image-192-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/24085320/image-192.png 1088w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43158901/jim-cramer-says-this-tech-stock-is-speculative-but-he-likes-it">Jim Cramer Says This Tech Stock Is Speculative But He Likes It</a></li>
</ul>

PLXS

These Analysts Raise Their Forecasts On Plexus Following Q1 Results

Donald Trump is back in the White House and Medicaid is in the spotlight. With a nearly $900 billion price tag, the program that <a href="https://www.kff.org/report-section/medicaid-enrollment-and-unwinding-tracker-enrollment-data/#:~:text=There%20are%2079.4%20million%20people,Figure%202%20and%20Table%201).">serves 79 million low-income or disabled Americans</a> is now a major target for cuts. Republicans are pushing for big changes, which could mean fewer options and higher health care costs for many families.
Medicaid's expansion under the Affordable Care Act (ACA) <a href="https://www.benzinga.com/general/biotech/24/11/42192091/biden-proposes-medicare-medicaid-access-for-popular-weight-loss-drugs">added 20 million people </a>to the program over the past 11 years. But the GOP wants to roll back that expansion and tighten funding. Trump has said he wants to drastically cut government spending and Medicaid seems to be in the crosshairs.
&#8220;Without them, we will watch this country sadly enter into fiscal collapse,&#8221; Rep. Jodey Arrington (R-Texas), chair of the House Budget Committee, told KFF.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a> </li>
</ul>
Work Requirements And Funding Cuts
Republicans are also considering bringing back work requirements, a policy Trump tried during his first term. Critics argue this will not reduce costs but add layers of bureaucracy. Rep. Chip Roy (R-Texas) told KFF that the goal is "wholesale reform" of health care spending, including scaling back ACA expansions.
"We should absolutely note that we are subsidizing the healthy, able-bodied Medicaid expansion population at a higher rate than we do the poorest and sickest among us," Arrington added.
Proposals include shifting Medicaid to block grants, cutting federal matching funds and requiring states to reapply for waivers that allow continuous eligibility. All these moves aim to save money – but at what cost?
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
Who Loses Out?
For low-income families, these cuts could be devastating. <a href="https://www.benzinga.com/news/earnings/24/10/41405992/elevance-cvs-unitedhealth-struggle-with-rising-medical-costs-after-covid-19-medicaid-policy-ends">Medicaid is often the last safety net </a>for those without employer-sponsored insurance. Cutting eligibility or adding more hurdles could leave millions uninsured.
Joan Alker, executive director of Georgetown University's Center for Children and Families, called the situation dire. "Medicaid is an obvious target for huge cuts," she told KFF. "An existential fight about Medicaid's future likely lies ahead."
Already, Medicaid has faced major disruptions. After pandemic-era protections expired in 2023, more than 25 million people lost coverage. Experts say this could pale compared to the cuts Republicans are now proposing.
See Also: The average 401(k) balance soars to a record-breaking high – <a href="https://www.benzinga.com/money/average-401k-balances-soars-to-record-high">Here's how to know if your nest egg is keeping pace.</a>
The Bigger Picture
If <a href="https://www.benzinga.com/general/health-care/24/11/42077057/trump-picks-dr-oz-as-centers-for-medicare-and-medicaid-services-administrator">Medicaid funding </a>is slashed, taxpayers could still end up footing the bill in other ways. Without Medicaid, many low-income families would struggle to afford private insurance with high premiums and deductibles.
Matt Salo, former executive director of the National Association of Medicaid Directors, warns of a "seismic shift" in how Medicaid operates. "A lot of powerful entities … want to see Medicaid work efficiently and be adequately funded," he said to KFF. "And they will be highly motivated to push back on something they see as draconian cuts."
The fight over Medicaid's future is just beginning. And for millions of Americans, what happens next could determine whether they can afford the care they need.
Read Next:
<ul>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>

Personal Finance

'An Existential Fight Ahead': Why Trump's Medicaid Cuts Could Leave Millions Struggling With Healthcare Costs

Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) has outperformed the market over the past 20 years by 4.13% on an annualized basis producing an average annual return of 12.64%. Currently, Norfolk Southern has a market capitalization of $57.24 billion. 
Buying $100 In NSC: If an investor had bought $100 of NSC stock 20 years ago, it would be worth $1,086.53 today based on a price of $253.00 for NSC at the time of writing.
<h3>Norfolk Southern's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737729911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Cann American

Cann American (CNNA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga